Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes

Protein Science

Volumn 20, Issue 2, 2011, Pages 366-378

  Thompson, Lawrence C ^a   Goswami, Sumit ^a   Peterson, Cynthia B ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Metals; PAI 1; Serpins; Vitronectin

Indexed keywords

CALCIUM; COBALT; COPPER; MAGNESIUM; MANGANESE; METAL DERIVATIVE; NICKEL; PLASMA PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITOR; VITRONECTIN;

ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; DISSOCIATION CONSTANT; HUMAN; METAL BINDING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTEIN STRUCTURE; STEADY STATE; SURFACE PLASMON RESONANCE;

BINDING SITES; CHLORIDES; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; METALS, HEAVY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STABILITY; SPECTROMETRY, FLUORESCENCE; SURFACE PLASMON RESONANCE; TEMPERATURE;

EID: 79251535901     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.567     Document Type: Article

References (65)

1. Dudev T, Lim C (2008) Metal binding affinity and selectivity in metalloproteins: insights from computational studies. Annu Rev Biophys 37:97-116.
2. Lovell T, Himo F, Han WG, Noodleman L (2003) Density functional methods applied to metalloenzymes. Coord Chem Rev 238:211-232.
3. Williams RJ (1997) The natural selection of the chemical elements. Cell Mol Life Sci 53:816-829.
4. Zhang AS, Enns CA (2009) Iron homeostasis: recently identified proteins provide insight into novel control mechanisms. J Biol Chem 284:711-715.
5. Turski ML, Thiele DJ (2009) New roles for copper metabolism in cell proliferation, signaling, and disease. J Biol Chem 284:717-721.
6. Eide DJ (2009) Homeostatic and adaptive responses to zinc deficiency in Saccharomyces cerevisiae. J Biol Chem 284:18565-18569.
7. Stout TJ, Graham H, Buckley DI, Matthews DJ (2000) Structures of active and latent PAI-1: a possible stabilizing role for chloride ions. Biochemistry 39:8460-8469. (Pubitemid 30489942)
8. Mathiasen L, Dupont DM, Christensen A, Blouse GE, Jensen JK, Gils A, Declerck PJ, Wind T, Andreasen PA (2008) A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state. Mol Pharmacol 74:641-653.
9. Li SH, Gorlatova NV, Lawrence DA, Schwartz BS (2008) Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands. J Biol Chem 283:18147-18157.
10. Wind T, Jensen JK, Dupont DM, Kulig P, Andreasen PA (2003) Mutational analysis of plasminogen activator inhibitor-1. Eur J Biochem 270:1680-1688.
11. Gils A, Pedersen KE, Skottrup P, Christensen A, Naessens D, Deinum J, Enghild JJ, Declerck PJ, Andreasen PA (2003) Biochemical importance of glycosylation of plasminogen activator inhibitor-1. Thromb Haemost 90: 206-217. (Pubitemid 37006281)
12. Blouse GE, Perron MJ, Kvassman JO, Yunus S, Thompson JH, Betts RL, Lutter LC, Shore JD (2003) Mutation of the highly conserved tryptophan in the serpin breach region alters the inhibitory mechanism of plasminogen activator inhibitor-1. Biochemistry 42: 12260-12272. (Pubitemid 37296503)
13. Hansen M, Busse MN, Andreasen PA (2001) Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitionsto latent and substrate forms. Eur J Biochem 268:6274-6283.
14. Vleugels N, Leys J, Knockaert I, Declerck PJ (2000) Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1. Thromb Haemost 84: 871-875.
15. Mangs H, Sui GC, Wiman B (2000) PAI-1 stability: the role of histidine residues. FEBS Lett 475:192-196.
16. Berkenpas MB, Lawrence DA, Ginsburg D (1995) Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J 14:2969-2977.
17. Lindahl TL, Sigurdardottir O, Wiman B (1989) Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 62:748-751.
18. Deng G, Curriden SA, Hu G, Czekay RP, Loskutoff DJ (2001) Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol 189:23-33.
19. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ (1996) Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134:1563-1571.
20. Deng G, Royle G, Wang S, Crain K, Loskutoff DJ (1996) Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem 271:12716-12723.
21. Kamikubo Y, De Guzman R, Kroon G, Curriden S, Neels JG, Churchill MJ, Dawson P, Oldziej S, Jagielska A, Scheraga HA, Loskutoff DJ, Dyson HJ (2004) Disulfide bonding arrangements in active forms of the somatomedin B domain of human vitronectin. Biochemistry 43:6519-6534. (Pubitemid 38697551)
22. Lawrence DA, Palaniappan S, Stefansson S, Olson ST, Francis-Chmura AM, Shore JD, Ginsburg D (1997) Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. J Biol Chem 272:7676-7680. (Pubitemid 27137317)
23. Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ (2003) How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 10:541-544.
24. Czekay RP, Loskutoff DJ (2009) Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism. J Cell Physiol 220:655-663.
25. Lijnen HR (2005) Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 3:35-45.
26. Webb DJ, Thomas KS, Gonias SL (2001) Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J Cell Biol 152:741-752.
27. Schvartz I, Seger D, Shaltiel S (1999) Vitronectin. Int J Biochem Cell Biol 31:539-544.
28. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y (1999) The plasminogen activator system: biology and regulation. Cell Mol Life Sci 56:104-132.
29. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA (1997) Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 100:58-67.
30. Tomasini BR, Mosher DF (1991) Vitronectin. Prog Hemost Thromb 10:269-305.
31. Preissner KT, Wassmuth R, Muller-Berghaus G (1985) Physicochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J 231:349-355.
32. Park YJ, Liu G, Lorne EF, Zhao X, Wang J, Tsuruta Y, Zmijewski J, Abraham E (2008) PAI-1 inhibits neutrophil efferocytosis. Proc Natl Acad Sci USA 105:11784-11789.
33. Dellas C, Loskutoff DJ (2005) Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 93:631-640.
34. Esmon CT (2004) Crosstalk between inflammation and thrombosis. Maturitas 47:305-314.
35. Thompson LC, Goswami S, Ginsberg DS, Day DE, Verhamme IM, Peterson CB (2011) Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease activity. Prot Sci 20:353-365.
36. Copeland RA (2000) Enzymes: a practical introduction to structure, mechanism, and data analysis, 2nd ed. USA: Wiley-VCH.
37. O'Keeffe ET, Hill RL, Bell JE (1980) Active site of bovine galactosyltransferase: kinetic and fluorescence studies. Biochemistry 19:4954-4962.
38. Pereira-Mouries L, Almeida MJ, Ribeiro C, Peduzzi J, Barthelemy M, Milet C, Lopez E (2002) Soluble silklike organic matrix in the nacreous layer of the bivalve Pinctada maxima. Eur J Biochem 269:4994-5003.
39. Magyar JS, Godwin HA (2003) Spectropotentiometric analysis of metal binding to structural zinc-binding sites: accounting quantitatively for pH and metal ion buffering effects. Anal Biochem 320:39-54.
40. Anwar ZM, Azab HA (1999) Ternary complexes in solution. Comparison of the coordination tendency of some biologically important zwitterionic buffers toward the binary complexes of some transition metal ions and some amino acids. J Chem Eng Data 44: 1151-1157.
41. Scheller KH, Abel THJ, Polanyi PE, Wenk PK, Fischer BE, Sigel H (1980) Metal ion-buffer interactions. II. Stability of binary and ternary complexes containing 2- [bis(2-hydroxyethyl)amino]-2(hydroxymethyl)-1,3-propanediol (Bis-Tris) and adenosine 50-triphosphate (Atp). Eur J Biochem 107:455-466.
42. Morgenstern R, Svensson R, Bernat BA, Armstrong RN (2001) Kinetic analysis of the slow ionization of glutathione by microsomal glutathione transferase MGST1. Biochemistry 40:3378-3384.
43. Kim YB, Kalinowski SS, Marcinkeviciene J (2007) A pre-steady state analysis of ligand binding to human glucokinase: evidence for a preexisting equilibrium. Biochemistry 46:1423-1431.
44. Verheyden S, Sillen A, Gils A, Declerck PJ, Engelborghs Y (2003) Tryptophan properties in fluorescence and functional stability of plasminogen activator inhibitor 1. Biophys J 85:501-510. (Pubitemid 36753654)
45. Stout TJ, Graham H, Buckley DI, Matthews DJ (2000) Structures of active and latent PAI-1: a possible stabilizing role for chloride ions. Biochemistry 39:8460-8469.
46. Nar H, Bauer M, Stassen JM, Lang D, Gils A, Declerck PJ (2000) Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J Mol Biol 297:683-695.
47. Jensen JK, Gettins PG (2008) High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling. Protein Sci 17:1844-1849.
48. Sharp AM, Stein PE, Pannu NS, Carrell RW, Berkenpas MB, Ginsburg D, Lawrence DA, Read RJ (1999) The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure 7:111-118.
49. Dupont DM, Blouse GE, Hansen M, Mathiasen L, Kjelgaard S, Jensen JK, Christensen A, Gils A, Declerck PJ, Andreasen PA, Wind T (2006) Evidence for a prelatent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C. J Biol Chem 281: 36071-36081.
50. Hagglof P, Bergstrom F, Wilczynska M, Johansson LB, Ny T (2004) The reactive-center loop of active PAI-1 is folded close to the protein core and can be partially inserted. J Mol Biol 335:823-832.
51. Aertgeerts K, De Bondt HL, De Ranter CJ, Declerck PJ (1995) Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nat Struct Biol 2:891-897.
52. Baker D, Agard DA (1994) Kinetics versus thermodynamics in protein folding. Biochemistry 33:7505-7509.
53. Kvassman JO, Verhamme I, Shore JD (1998) Inhibitory mechanism of serpins: loop insertion forces acylation of plasminogen activator by plasminogen activator inhibitor-1. Biochemistry 37:15491-15502.
54. Olson ST, Swanson R, Day D, Verhamme I, Kvassman J, Shore JD (2001) Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor- 1, with tissue plasminogen activator and trypsin. Biochemistry 40:11742-11756.
55. Linder MC, Hazegh-Azam M (1996) Copper biochemistry and molecular biology. Am J Clin Nutr 63:797S-811S.
56. Kramer ML, Kratzin HD, Schmidt B, Romer A, Windl O, Liemann S, Hornemann S, Kretzschmar H (2001) Prion protein binds copper within the physiological concentration range. J Biol Chem 276:16711-16719.
57. Osterberg R (1980) Physiology and pharmacology of copper. Pharmacol Ther 9:121-146.
58. Nalbandyan RM (1983) Copper in brain. Neurochem Res 8:1211-1232.
59. Hartter DE, Barnea A (1988) Brain tissue accumulates 67copper by two ligand-dependent saturable processes. A high affinity, low capacity and a low affinity, high capacity process. J Biol Chem 263:799-805.
60. Podor TJ, Peterson CB, Lawrence DA, Stefansson S, Shaughnessy SG, Foulon DM, Butcher M, Weitz JI (2000) Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. J Biol Chem 275:19788-19794.
61. Podor TJ, Campbell S, Chindemi P, Foulon DM, Farrell DH, Walton PD, Weitz JI, Peterson CB (2002) Incorporation of vitronectin into fibrin clots. Evidence for a binding interaction between vitronectin and gamma A/ gamma' fibrinogen. J Biol Chem 277:7520-7528.
62. Finney L, Vogt S, Fukai T, Glesne D (2009) Copper and angiogenesis: unravelling a relationship key to cancer progression. Clin Exp Pharmacol Physiol 36:88-94.
63. Finney L, Mandava S, Ursos L, Zhang W, Rodi D, Vogt S, Legnini D, Maser J, Ikpatt F, Olopade OI, Glesne D (2007) X-ray fluorescence microscopy reveals largescale relocalization and extracellular translocation of cellular copper during angiogenesis. Proc Natl Acad Sci USA 104:2247-2252.
64. Mou X, Peterson CB, Prosser RA (2009) Tissue-type plasminogen activator-plasmin-BDNF modulate glutamate- induced phase-shifts of the mouse suprachiasmatic circadian clock in vitro. Eur J Neurosci 30:1451-1460.
65. Rich RL, Myszka DG (2001) BIACORE J: a new platform for routine biomolecular interaction analysis. J Mol Recognit 14:223-228.